<DOC>
	<DOC>NCT00600366</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on blood glucose control in insulin naive type 2 diabetes failing on secondary oral hypoglycaemic agent (OHA).</brief_summary>
	<brief_title>Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPenÂ® in Insulin Naive Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 2 diabetes Insulin naive diabetes Current treatment with OHA, secondary failure Body mass index (BMI) below 40 kg/m2 HbA1c over 8.5% Willing and able to start with insulin therapy and to perform selfblood glucose monitoring History of drug or alcohol abuse Receipt of the investigational drug within the last month prior to this trial Known or suspected allergy to trial products or related products Severe uncontrolled hypertension Any disease or condition, which the Investigator feels, would interfere with the trial</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>